Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07145177CT.gov 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04399876CT.gov Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer | — | Enrolling By Invitation | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT02494713CT.gov Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT01848067CT.gov Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT00307294CT.gov Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | — | Completed | — | — | — |
NCT00260611CT.gov Study of Oxaliplatin and Taxotere in Prostate Cancer | — | Completed | — | — | — |
NCT00081159CT.gov Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | — | Completed | — | — | — |
NCT00456989CT.gov Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00132756CT.gov Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | — | Terminated | — | — | — |
Show 14 more trialsShow fewer
NCT00186420CT.gov Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation | — | Completed | — | — | — |
NCT00061867CT.gov Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00030654CT.gov Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00215345CT.gov A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | — | Unknown | — | — | — |
NCT00024167CT.gov Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00080782CT.gov Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases | — | Terminated | — | — | — |
NCT00036790CT.gov Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00014352CT.gov Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00004014CT.gov Liposomal Doxorubicin in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00003084CT.gov Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00003038CT.gov Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00002855CT.gov Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | — | Completed | — | — | — |
NCT00002721CT.gov Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00811031CT.gov Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | University of California, San Francisco | P3 | B · 62 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →